#United States #Pittsburgh #PANTHERx Rare #Chiesi Group #MYCAPSSA

PANTHERx® Rare Partners with Chiesi for MYCAPSSA® Distribution

In a significant development for patients managing acromegaly, PANTHERx® Rare has been selected by Chiesi as the sole specialty pharmacy to distribute MYCAPSSA® (octreotide). This partnership underscores a commitment to improve accessibility and personalized support for those living with the condition.

Understanding MYCAPSSA®

MYCAPSSA® is an oral somatostatin analog designed specifically for long-term management of acromegaly. Patients who have responded well to octreotide or lanreotide will now have an alternative treatment option that can be administered orally, marking a substantial shift in treatment methodologies. For individuals affected by acromegaly, this is vital, as it allows for a more convenient way to manage a condition that necessitates strict adherence to medication regimens.

The Impact of Acromegaly

Acromegaly is characterized by excessive growth hormone production by the pituitary gland—a condition often caused by a benign tumor known as a pituitary adenoma. Symptoms can be diverse, ranging from noticeable enlargement of hands and feet to changes in facial features, as well as thickened skin and deeper voice. Furthermore, patients may experience severe complications such as type 2 diabetes, hypertension, heart disease, and increased risk for arthritis.

Treatments traditionally involve surgical interventions, medications, and radiation therapies, each accompanied by their own challenges and limitations. The introduction of MYCAPSSA® gives patients a new option in their therapeutic arsenal.

A Commitment to Accessibility

Bansi Nagji, CEO of PANTHERx Rare, expressed enthusiasm about this new partnership, emphasizing their mission to support individuals and families affected by rare diseases. "At PANTHERx, we stand by those living with rare conditions who often face significant barriers to access and mobility in treatment options. This partnership with Chiesi reinforces our commitment to provide comprehensive support to the acromegaly community."

The selection of PANTHERx as Chiesi's exclusive pharmacy is particularly meaningful, as it allows for streamlined access to necessary medications for a demographic that has struggled with access in the healthcare ecosystem. Patients relying on MYCAPSSA® will benefit from PANTHERx’s specialized knowledge and services focused on rare diseases, ensuring they receive tailored care and support throughout their treatment journey.

About the Companies

PANTHERx Rare

PANTHERx Rare is renowned as The Rare Disease Pharmacy®, specializing exclusively in the distribution of treatments for rare and orphan diseases. The pharmacy has garnered numerous accolades for its commitment to patient-centered care, including the MMIT Patient Choice Award for eight consecutive years. PANTHERx aims to transform lives through innovative therapies, clinical expertise, and dedicated support services, establishing itself as a pioneer in the rare disease sector.

Chiesi Global Rare Diseases

Chiesi Global Rare Diseases operates under the Chiesi Group, focused on providing innovative therapies for individuals grappling with rare conditions. The organization emphasizes equal access to treatment for all, reflecting its dedication to the welfare of patients globally. As a family-operated business, Chiesi Group holds true to its mission of creating a world where every ailment can be treated effectively.

Looking Ahead

This collaboration between PANTHERx Rare and Chiesi signals a promising transformation in the landscape of acromegaly treatment. With the introduction of MYCAPSSA®, patients may find renewed hope in their treatment options—an essential step towards enhancing their quality of life. As healthcare continues to evolve, the commitment of both companies to patient access and support remains a beacon for those affected by rare diseases. For more details on MYCAPSSA® and services from PANTHERx, visit pantherxrare.com.